Welcome to our dedicated page for Kamada SEC filings (Ticker: KMDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Kamada Ltd (KMDA) SEC filings page on Stock Titan provides access to the company’s public reports as a foreign private issuer. Kamada files current reports on Form 6-K under the Securities Exchange Act of 1934, which include press releases, financial statements, presentations and other shareholder communications.
For Kamada, these filings are a primary source of information on its specialty plasma-derived therapies business, including proprietary products such as KEDRAB®, CYTOGAM®, GLASSIA®, WINRHO SDF®, VARIZIG® and HEPAGAM B®, as well as KAMRAB®, KAMRHO (D)® and equine-based anti-snake venom products. Recent 6-Ks have attached quarterly and nine-month consolidated financial statements, discussions of revenues and adjusted EBITDA, and details on the performance of the Proprietary Products and Distribution segments.
Filings also document clinical and operational milestones, such as the discontinuation of the InnovAATe Phase 3 trial of Inhaled AAT following an interim futility analysis, the initiation of the investigator-initiated SHIELD study for CYTOGAM in kidney transplantation, and regulatory approvals for Kamada’s plasma collection center in Houston, Texas. Additional 6-Ks provide notices of annual general meetings, investor conference participation, and extensions of supply tenders, for example with Canadian Blood Services.
On Stock Titan, Kamada’s filings are updated as they are released to EDGAR, and AI-powered tools summarize key points from each document to help users interpret complex disclosures. Investors can review attached financial statements, presentations, and exhibits listed in the 6-K exhibit indexes, and track how Kamada reports on its growth pillars, plasma collection expansion, and business development activities over time.
KAMADA LTD executive Livneh Nir, the company’s VP and General Counsel, filed an initial Form 3 reporting holdings of stock options on ordinary shares. The filing lists several option grants with exercise prices of 5.6200 and 7.5500, expiring between 2029-10-23 and 2035-10-22. The options, covering blocks such as 9,485, 10,000 and 15,000 underlying ordinary shares, are held directly and are exercisable using a net-exercise method.
Kamada Ltd. files its 2025 annual report, outlining its plasma-derived biopharmaceutical business, risk profile, and capital structure. As of December 31, 2025, it had 57,686,056 Ordinary Shares outstanding. Most revenue comes from its Proprietary Products segment, which supplied about 87% of total revenues in 2025.
The company is highly dependent on a few key therapies and partners. KEDRAB, GLASSIA, its CMV immune globulin product, and GLASSIA royalties together contributed roughly 59% of 2025 revenue, with about 55% of total revenues generated in the United States. Kamada receives GLASSIA royalties from Takeda at 12% of net sales through August 2025 and 6% thereafter until 2040, with a minimum of $5 million per year.
The report highlights concentration risks around Kedrion, which distributes KEDRAB in the U.S. under an agreement projecting approximately $180 million of minimum purchases over 2024–2027, and around key plasma suppliers and contract manufacturers. Kamada is investing in three U.S. plasma collection centers to secure specialty plasma and sell normal source plasma but notes execution, regulatory, and donor-availability risks.
Kamada Ltd. reported record 2025 results and introduced an ongoing dividend. Total revenues reached $180.5 million, up 12% year over year, with adjusted EBITDA of $42.0 million, a 23% increase. Net income was $20.2 million, or $0.35 per share, and cash and cash equivalents were $75.5 million as of December 31, 2025.
The Board declared a cash dividend of $0.25 per share, totaling about $14.4 million, payable April 6, 2026 to shareholders of record on March 23, 2026. Kamada also adopted an annual dividend policy targeting distributions of at least 50% of annual net income, subject to Board discretion and Israeli law tests.
For 2026, management affirmed guidance of $200–$205 million in revenues and $50–$53 million in adjusted EBITDA, implying continued double-digit organic growth. The company highlights multiple growth pillars, including specialty plasma therapies, distribution partnerships, plasma collection, and potential M&A.
Kamada Ltd. filed a Form 6-K to notify investors that it will release its fiscal year and fourth quarter 2025 financial results on March 11, 2026, before U.S. market open. Management will host an investment community conference call that day at 8:30am Eastern Time.
The notice also highlights Kamada’s focus on specialty plasma-derived therapies for rare and serious conditions, its three plasma collection centers in Texas, and its growth strategy based on organic expansion, in-licensing, plasma collection, and potential mergers and acquisitions.
Kamada Ltd. is providing a positive outlook for the next two years. For 2026, the company guides to revenues of $200–$205 million and $50–$53 million of adjusted EBITDA, which it says reflects double-digit profitable growth based solely on continued organic expansion of its proprietary plasma therapies and distribution businesses. The midpoint of this range represents about a 13% revenue increase and 23% adjusted EBITDA increase over its 2025 guidance midpoints.
Kamada also affirms its 2025 guidance of $178–$182 million in revenues and $40–$44 million of adjusted EBITDA, and it expects 2025 year-end cash of approximately $75 million. Management cites growth across its global portfolio, including products such as KAMRAB, GLASSIA, HEPAGAM and VARIZIG, launches of biosimilars in Israel, expansion of its distribution business into the MENA region, and increasing plasma collection in its three U.S. centers, even as a reduced GLASSIA royalty rate from Takeda weighs on 2026.
Kamada Ltd. submitted a Form 6-K as a foreign private issuer, highlighting an attached exhibit about a commercial development. The exhibit states that Kamada announced a $10–$14 million extension of a Canadian supply tender. This indicates that an existing Canadian supply arrangement has been extended with an estimated value in that range, and the company is formally updating investors by incorporating this report into several existing Form S-8 registration statements.
Kamada Ltd. furnished a Form 6-K that includes a press release reporting strong third-quarter and nine‑month 2025 results, highlighting over 30% year‑over‑year profitability growth. The filing also provides a November 2025 company presentation and unaudited consolidated financial statements as of September 30, 2025. This 6‑K is incorporated by reference into Kamada’s Form S‑8 registration statements.
Kamada Ltd. furnished a Form 6-K and attached an exhibit announcing a clinical milestone for CYTOGAM. The filing states it is incorporated by reference into the company’s Form S-8 registration statements.
Exhibit 99.1 is titled “Kamada Announces First Patient Enrolled into an Investigator-Initiated Clinical Trial of CYTOGAM® to Prevent Cytomegalovirus in Kidney Transplantation.” This indicates the study is led by independent investigators and marks the start of patient enrollment focused on CMV prevention in kidney transplant recipients. The report was signed by Nir Livneh, Vice President General Counsel and Corporate Secretary.
Kamada Ltd. announced it will hold its Annual General Meeting of Shareholders on December 10, 2025 at 4:00 p.m. Israel time at the company’s offices, 2 Holzman Street, Weizmann Science Park, Rehovot, Israel.
The report states that the Notice and Proxy Statement and the proxy card are attached as Exhibits 99.1 and 99.2 and incorporated by reference. The Form 6-K is also incorporated by reference into Kamada’s Form S-8 registration statements (File Nos. 333-192720, 333-207933, 333-215983, 333-222891, 333-233267, 333-265866).